As of 2015, there is no existing evidence suggesting NovoDalin B17 can cure cancer, according to the Memorial Sloan Kettering Cancer Center. In fact, research suggests NovoDalin B17 treatment can be detrimental to a person's health and cause cyanide toxicity.
NovoDalin B17 is also called amygdalin, or vitamin B17. In one study, amygdalin plus metabolic therapy was administered to 178 patients with various forms and stages of cancer, explains the Memorial Sloan Kettering Cancer Center. At the beginning of the study, all of the patients were in good health and one-third of them had not yet received treatment for their disease. For three weeks, each study participant received amygdalin, both orally and intravenously, with a combination of minerals, vitamins and enzyme supplements. Each patient was encouraged to cut eggs, dairy, caffeine and alcoholic beverages from his diet. After the treatment, only one patient showed positive results. After three months, 91% of patients showed a progression in their disease.
It was determined from the study that amygdalin was not an effective treatment for cancer. In fact, amygdalin treatment caused cyanide toxicity in many of the patients, notes the Memorial Sloan Kettering Cancer Center. Some of the side effects of the treatment included headache, nausea, vomiting and dizziness. There is also no evidence to support a vitamin B17 deficiency can cause cancer. As of 2015, amygdalin is banned in the United States.